Divide And Conquer With Biomarkers: An Interview With Interleukin Genetics CEO Lewis Bender (Part 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Segmenting large markets using biomarkers is a logical “insurance policy” to help protect big bets in development. If only pharma companies would consider the idea outside oncology.
You may also be interested in...
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
“The Right Approach” To Regulating Biomarkers: An Interview With Interleukin Genetics CEO Lewis Bender (Part 3)
Setting standards in an emerging area of science is a big challenge, both for FDA and regulated industry. One diagnostics CEO thinks FDA is taking an appropriately careful approach.